Development
Takeda Pharmaceutical Company Limited
TAK
$15.52
$0.211.37%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 7.53B | 7.22B | 7.71B | 7.23B | 7.78B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.53B | 7.22B | 7.71B | 7.23B | 7.78B |
| Cost of Revenue | 2.57B | 2.38B | 2.34B | 2.27B | 2.38B |
| Gross Profit | 4.96B | 4.84B | 5.37B | 4.96B | 5.39B |
| SG&A Expenses | 1.81B | 1.75B | 1.81B | 1.93B | 1.86B |
| Depreciation & Amortization | 930.45M | 1.66B | 885.96M | 573.63M | 961.62M |
| Other Operating Expenses | 234.09M | 496.39M | 208.79M | -109.78M | 291.40M |
| Total Operating Expenses | 6.82B | 7.56B | 6.43B | 5.87B | 6.74B |
| Operating Income | 710.78M | -341.56M | 1.29B | 1.36B | 1.04B |
| Income Before Tax | 415.03M | -664.40M | 983.88M | 362.21M | 760.02M |
| Income Tax Expenses | -301.46M | -332.33M | 332.45M | 126.84M | -85.09M |
| Earnings from Continuing Operations | 716.49M | -332.07M | 651.43M | 235.37M | 845.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -243.90K | -408.40K | -80.10K | -15.10K | -156.00K |
| Net Income | 716.24M | -332.48M | 651.35M | 235.35M | 844.95M |
| EBIT | 710.78M | -341.56M | 1.29B | 1.36B | 1.04B |
| EBITDA | 1.98B | 923.12M | 2.53B | 2.02B | 2.30B |
| EPS Basic | 0.46 | -0.21 | 0.42 | 0.15 | 0.54 |
| Normalized Basic EPS | 0.17 | -0.27 | 0.42 | 0.39 | 0.31 |
| EPS Diluted | 0.45 | -0.21 | 0.42 | 0.15 | 0.54 |
| Normalized Diluted EPS | 0.16 | -0.27 | 0.42 | 0.39 | 0.30 |
| Average Basic Shares Outstanding | 1.57B | 1.57B | 1.55B | 1.56B | 1.55B |
| Average Diluted Shares Outstanding | 1.59B | 1.57B | 1.57B | 1.56B | 1.57B |
| Dividend Per Share | 0.00 | 0.65 | -- | 0.68 | 0.00 |
| Payout Ratio | 130.77% | -18.87% | 146.26% | 33.47% | 108.28% |